Efficacy of Metformin Monotherapy 1Gm in Newly Diagnosed Type 2 Diabetes Mellitus-A Prospective Open Label Study

Diabetes mellitus is a chronic crippling cellular disorder that causes serious disruption and malfunction of biological enzymes causing to chronic hyperglycemia, resulting to micro and macro arterial abnormalities. The occurrence of diabetes is rising rapidly, leads to an increase in death and mortality in India. The main objective of treatment for type 2 diabetes mellitus (T2DM) is to attain and preserve excellent glycemic control and to decrease the mortality and threat of microvascular and macrovascular problems..Metformin is the first-line and most usually prescribed anti-hyperglycaemic drug in patients with type 2 diabetes. It may be used as monotherapy or in conjunction with many other oral anti-hyperglycaemic drugs or insulin.

In this study a total of 50 patients who fulfilled the eligibility criteria were enrolled. And they were subjected to trial medication tablet metformin 500mg twice daily and patients baseline line investigations fasting blood glucose and postprandial blood glucose were collected and they advised to followup for 3months and 6 months and any adverse events during the study period were reported and it was recorded and managed appropriately.

Baseline FBS and PPBS baseline values expressed as Mean±SD were 138.06±17.12 mg/dl and 223.12±30.63 mg/dl respectively. After 6 months of metformin therapy, FBS and PPBS were 91.64±10.55 mg/dl and 133.88±7.99 mg/dl respectively.

The current study summates that metformin 1gm monotherapy in newly diagonosed type 2 diabetes mellitus showed effective gylcemic control for period of six months and this proves that metformin is a effective and gold standard antidiabetic agent and thereby reducing macro and micro complications at the initial stage of disease.